Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study

被引：2
|
作者：
Graff, J. N. [1 ]
Burotto, M. [2 ]
Fong, P. C. [3 ]
Pook, D. [4 ]
Zurawski, B. [5 ]
Kopp, R. Manneh [6 ]
Salinas, J. E. [7 ]
Bylow, K. [8 ,9 ]
Kramer, G. [10 ]
Ratta, R. [11 ]
Kwiatkowski, M. [12 ]
Retz, M. [13 ]
Kwak, C. [14 ]
Arija, J. A. Arranz [15 ]
Gurney, H. P. [16 ]
Matsubara, N. [17 ]
Liang, L. W. [18 ]
Todoric, J. [18 ]
Imai, K. [18 ]
Stenzl, A. [19 ]
机构：
[1] OHSU Oregon Hlth Sci Univ, Hematol Oncol Dept, Portland, OR USA
[2] Bradford Hill Clin Ctr, Med Oncol Dept, Recoleta, Chile
[3] Auckland City Hosp, Med Oncol Dept, Auckland, New Zealand
[4] Monash Hlth, Monash Med Ctr, Oncol Dept, Clayton, Vic, Australia
[5] Prof Franciszek Lukaszczyk Oncol Ctr, Oncol, Bydgoszcz, Poland
[6] Sociedad Oncol & Hematol Cesar, Dept Med Oncol, Valledupar, Colombia
[7] Hosp Prov Cordoba, Oncol, Cordoba, Spain
[8] Froedtert Hosp, Med Oncol, Milwaukee, WI USA
[9] Med Coll Wisconsin, Milwaukee, WI USA
[10] Med Univ Vienna, Urol, Vienna, Austria
[11] Hop Foch, Dept Med Oncol, Suresnes, France
[12] Szpital Wojewodzki Mikolaja Kopernika, Oddzial Dzienny Chemioterapii, Koszalin, Poland
[13] Tech Univ Munich, Rechts Isar Med Ctr, Urol, Munich, Germany
[14] Seoul Natl Univ, Coll Med, Urol, Yeongeon Med Campus, Seoul, South Korea
[15] Hosp Gen Univ Gregorio Maranon, Med Oncol, Madrid, Spain
[16] Macquarie Univ, Med Oncol, Fac Med Hlth & Human Sci, Sydney, NSW, Australia
[17] Natl Canc Ctr Hosp East, Dept Med Oncol, Kashiwa, Chiba, Japan
[18] Merck Co Inc, Oncol, Rahway, NJ USA
[19] Univ Tubingen, Urol Dept, Crona Kliniken, Tubingen, Germany
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2721
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1771MO
引用
收藏
页码：S957 / S957
页数：1
相关论文
共 50 条
  • [41] Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study
    Graff, Julie N.
    Hoimes, Christopher J.
    Gerritsen, Winald R.
    Vaishampayan, Ulka N.
    Elliott, Tony
    Hwang, Clara
    ten Tije, Albert J.
    Omlin, Aurelius
    McDermott, Raymond S.
    Fradet, Yves
    Tagawa, Scott T.
    Kilari, Deepak
    Ferrario, Cristiano
    Uemura, Hiroji
    Jones, Robert J.
    Fukasawa, Satoshi
    Peer, Avivit
    Niu, Cuizhen
    Poehlein, Christian H.
    Qiu, Ping
    Suttner, Leah
    de Wit, Ronald
    Schloss, Charles
    de Bono, Johann S.
    Antonarakis, Emmanuel S.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024,
  • [42] PROSPER: A Phase 3, Randomized, Double-Blind, Placebo (PBO)-Controlled Study of Enzalutamide (ENZA) in Menwith Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
    Stockler, M. R.
    Hussain, M.
    Fizazi, K.
    Saad, F.
    Rathenborg, P.
    Shore, N.
    Demirhan, E.
    Modelska, K.
    Phung, D.
    Krivoshik, A.
    Sternberg, C. N.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 53 - 54
  • [43] Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.
    Massard, Christophe
    Retz, Margitta
    Hammerer, Peter
    Quevedo, Fernando
    Fong, Peter C. C.
    Berry, William R.
    Gurney, Howard
    Piulats, Josep M.
    Joshua, Anthony M.
    Linch, Mark David
    Kolinsky, Michael Paul
    Romano, Emanuela
    Sridhar, Srikala S.
    Conter, Henry Jacob
    Augustin, Marinela
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study
    Joshua, A. M.
    Gurney, H.
    Retz, M.
    Tafreshi, A.
    Fong, P. C. C.
    Shore, N. D.
    Romano, E.
    Augustin, M.
    Piulats, J. M.
    Berry, W. R.
    Kolinsky, M. P.
    Sridhar, S. S.
    Conter, H. J.
    Todenhoefer, T.
    Appleman, L. J.
    Wu, H.
    Schloss, C.
    Poehlein, C. H.
    de Bono, J. S.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1325 - S1325
  • [45] Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).
    Mehra, Niven
    Antonarakis, Emmanuel S.
    Park, Se Hoon
    Goh, Jeffrey C.
    McDermott, Raymond S.
    Gonzalez, Nuria Sala
    Fong, Peter C. C.
    Greil, Richard
    De Santis, Maria
    Yanez, Patricio Eduardo
    Huang, Yi-Hsiu
    Begbie, Stephen
    Rey, Felipe
    Kramer, Gero
    Suzuki, Hiroyoshi
    Saretsky, Todd L.
    Ghate, Sameer R.
    Cui, Yi
    Kim, Jeri
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [46] Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)
    Graff, Julie Nicole
    Cheng, Heather H.
    Vuky, Jacqueline
    Alumkal, Joshi J.
    Kreitner, Dustin
    Petreaca, Delia
    Grivas, Petros
    Schweizer, Michael Thomas
    Higano, Celestia S.
    Chen, Yiyi
    Yu, Evan Y.
    Beer, Tomasz M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [47] A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Powles, Thomas
    Fizazi, Karim
    Gillessen, Silke
    Drake, Charles G.
    Rathkopf, Dana E.
    Narayanan, Sujata
    Green, Marjorie C.
    Mecke, Almut
    Schiff, Christina
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.
    Yu, Evan Y.
    Piulats Rodriguez, Jose Maria M.
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Arranz Arija, Jose Angel
    Oudard, Stephane
    Fong, Peter C. C.
    Kolinsky, Michael Paul
    Augustin, Marinela
    Todenhofer, Tilman
    Kam, Audrey E.
    Gurney, Howard
    Tafreshi, Ali
    Retz, Margitta
    Berry, William R.
    Mar, Nataliya
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] Phase II study of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) and progression on enzalutamide (enza).
    Teply, Benjamin A.
    Wang, Hao
    Sullivan, Rana
    Rifkind, Irina
    Bruns, Ashley
    Decarli, Morgan
    Sinibaldi, Victoria J.
    Pratz, Caroline F.
    Luo, Jun
    Carducci, Michael Anthony
    Paller, Channing Judith
    Antonarakis, Emmanuel S.
    Eisenberger, Mario A.
    Denmeade, Samuel R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study
    Tombal, B.
    Goebell, P. J.
    Shore, N. D.
    George, D. J.
    Pinto, A.
    Sartor, O.
    Meltzer, J.
    Verholen, F.
    Schmall, A.
    Saad, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S984 - S984
12345